On Monday, Vincerx Pharma ( VINC ) shared updates on its ongoing Phase 1 studies of VIP943, VIP236, and enitociclib, which aim to address various blood cancers.

The ongoing Phase 1 dose-escalation study of VIP943 has enrolled 22 patients across several escalating dose cohorts (0.2 to 1.3 mg/kg once weekly).

One patient with relapsed acute myeloid leukemia (AML) achieved complete remission with incomplete hematologic improvement (CRi), and one patient with higher-risk myelodysplastic syndrome (HR-MDS) has achieved complete remission with limited count recovery (CRL)

VIP943 demonstrated effective binding to CD123+ cancer cells, with the highest dose cohort achieving 84% receptor occupancy. Preliminary pharmacokinetic (PK) and pharmacodynamic (PD) results showed low payload release and suggested the potential for twice-weekly dosing to improve outcomes.

The company anticipates providing another data update on the ongoing Phase 1 VIP943 study by the end of the year.

Vincerx also provided an update on VIP236 being tested in patients with advanced solid tumors. Out of 29 patients enrolled, 20 were evaluable for response, and nine patients achieved stable disease, showing a 45% disease control rate.

The company’s enitociclib shows potential in Phase 1 studies for relapsed/refractory diffuse large B-cell lymphoma and peripheral T-cell lymphoma.

As of September 2024, four out of seven patients have shown partial responses. Vincerx plans to partner for the continued development of enitociclib, underscoring its commitment to focus on VIP943.

Vincerx is seeking a strategic partner to advance the development of VIP236 and enitociclib.

By transitioning VIP236 to a partnering asset, the company plans to streamline its operations and focus its efforts on the continued development of its lead ADC, VIP943.

Price Action: VINC stock is down 25.3% at $0.52 at last check Tuesday.

Read Next:

Honeywell Seeks To Simplify Structure, Boost Flexibility With $10B Spin-Off Of Advanced Materials Unit.